After overexpression of PGC-1α in the muscle creatine kinase (MCK) promoter, it was found that there was no significant effect on muscle mass in young mice, but it could prevent myasthenia in aged mice by inhibiting protein degradation [65]; however, after overexpression of PGC1α in the human skeletal actin (HSA) promoter, muscle atrophy is observed at 25 weeks of age in mice [66]. This evidence concerns the gene PPARGC1A and Fatigable weakness.